Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fraunhofer IZI Granted Manufacturing Authorization for Second GMP Facility

Published: Thursday, January 23, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Company’s cleanroom capacities shall again be expanded by mid-2015.

On 10 January 2014, the existing manufacturing authorization according to Art. 13 of the German Drug Act (AMG) of the Fraunhofer Institute for Cell Therapy and Immunology IZI was expanded to cover the first extension of the existing cleanroom facility.

After extensive qualification and inspection by the Regional Council of Saxony, the »Certificate of GMP-Compliance of a Manufacturer« was also updated. This seal of approval doubles the institute's capacities to manufacture cell-based medicinal products, or so-called »Advanced Therapy Medicinal Products« (ATMP).

Cell therapy products for clinical studies can now be produced on a total cleanroom area of over 750 m² in sixteen cleanroom class B manufacturing rooms to be operated independently.

The specific facility design allows for the parallel manufacture of several cell therapy products without the risk of mutual cross-contamination.

A separate part of the facility is furthermore specifically designed for the manufacture of products that must meet special safety requirements with respect to genetic engineering or protection against infection.

The operation of two separate and independent facilities provides maximum flexibility and continuity in the manufacturing processes, especially for bridging regularly scheduled maintenance periods.

A major part of the new facility is already booked out with manufacturing projects for various different clinical studies up to Phase III.

The staff consisting of 61 qualified employees currently handles both GMP facilities, the associated projects and the comprehensive quality assurance system. These professionals have profound expertise in the production and quality control of autologous and allogeneic cell therapy products, process development, and the validation of production processes as well as quality controls.

The cleanroom capacities of the Fraunhofer IZI shall again be expanded with a third construction section by mid-2015 to meet the continuously growing demand in this business sector.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!